drugset
drugset / Trial / NCT00666497

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT00666497 ↗

Phase 2 Terminated 6 enrolled Mirati Therapeutics Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.

Timeline

Start
2008-06
Primary completion
2009-04
Completion
2009-04

Outcome

Outcome not reported

Stopped: “Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 with be closed.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Mocetinostat Small molecule 90 mg Oral

Indications

acute myeloid leukemia myelodysplastic syndrome